Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Diabetes Drugs Market: By Drugs: Oral Anti-diabetic Drugs, Insulin; By Diabetes Type: Type 1, Type 2; By Distribution Channel: Online, Hospital, Other; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics: SWOT Analysis; Value Chain Analysis; Competitive Landscape; Industry Events and Developments

Global Diabetes Drugs Market Outlook

The market for diabetes drugs reached a value of about USD 67.17 billion in 2021. The market is further expected to grow at a CAGR of about 5.3% in the forecast period of 2022-2027 to reach a value of around USD 91.57 billion by 2027.

 

Asia Pacific to be Among the Leading Regions Owing to the Increasing Diabetic Population

The Asia Pacific region accounts for a significant share of the global market as it has a large diabetic population, China alone has more than 120 million diabetic people, and the number does not seem to stop. The rising number of diabetes patients can be due to multiple reasons, such as changing lifestyles, unhealthy diet, overconsumption of junk food, and obesity, among others. Looking at the scenario, various companies are developing new and cost-effective alternatives, anti-diabetic drugs. They have started advertising their products and treatments to spread awareness about the same. In addition to favourable government reimbursement policies, increasing development for insulins and improving healthcare infrastructure are propelling the market for diabetic drugs.

The growing inclination toward junk foods is a major factor why people become diabetic. The lifestyle is becoming increasingly hectic, and the inclination toward junk and processed foods is constantly rising, which keeps the need for constant development in the medical field alive. New drugs, such as Canagliflozin and dapagliflozin, are getting approved for the treatment of diabetes, which opens up numerous opportunities for both new and established competitors in the global diabetic medications industry.

 

Market Segmentations: Diabetes Drugs Market

Diabetes is a disease that occurs when the blood sugar levels rise up to extremely high levels, affecting body functions and other disruptions in the body. It is a chronic disease, and the types can be divided into Type1 and Type2. Diabetes drugs are used to control the sugar level through oral administration of insulin in the main treatment.

The drug types in the market can be divided into the following:

  • Oral Anti-Diabetic Drugs
    • Alpha-Glucosidase Inhibitors
    • Biguanides 
    • Bile Acid Sequestrants
    • Dopamine-2 Agonists
    • DPP-4 inhibitors
    • Meglitinides
    • SGLT2 Inhibitors
    • Sulfonylureas
    • TZDs 
    • Oral Combination Therapy
  • Insulin
    • Insulin Glargine
    • Insulin Aspart
    • Human Insulin
    • Biosimilar Insulin

The types of diabetes can be divided into the following:

  • Type 1
  • Type 2

The distribution channels of the diabetes drug market

  • Online 
  • Hospital 
  • Retail Pharmacies

The regional markets for diabetes drugs market can be divided into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa.

 

The Increasing Diabetic Population Propelling the Market Growth

The market growth is majorly driven by the increasing cases of diabetes every day around the world. The degrading lifestyle and eating habits like excessive sugar-based food consumption, which does not seem to improve, are major reasons of concern as they can transform into other disorders like obesity, liver problems, and diabetes, among others. The demand for insulin is rising due to the increasing cases and especially among the type 1 diabetics, as the intake is greater in them.

To combat this ongoing issue, governments are increasing their investment in R&D. Healthcare organisations and pharmaceutical manufacturers are increasingly collaborating with the government to develop new products and cost-effective methods to support a wider group of population. The number of diabetes care centres is aiding the growth of the diabetes drugs market. Technological advancements in the diabetes diagnostics devices, such as portable glucometers, make it possible for people to track their blood glucose levels, and the increasing availability of these devices will drive the growth of the market as when the people become aware of the situation, they will be more likely to get treatment, which simultaneously raises the market for diabetes drugs.

 

Key Players in the Global Market for Diabetic Drugs

The report gives a detailed analysis of the following key players in the global diabetes drugs market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Novo Nordisk A/S
  • Sanofi-aventis Groupe
  • Merck & Co., Inc.
  • Eli Lilly and Company.
  • AstraZeneca plc
  • Takeda Pharmaceutical Company Limited.
  • Novartis AG
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2021
Historical Period 2017-2021
Forecast Period 2022-2027
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drugs
  • Diabetes Type
  • Distribution Channel
  • Region
Breakup by Drugs 
  • Oral Anti-diabetic Drugs
    • Alpha-glucosidase Inhibitors
    • Biguanides
    • Bile Acid Sequestrants
    • Dopamine-2 Agonists
    • DPP-4 inhibitors
    • Meglitinides
    • SGLT2 Inhibitors
    • Sulfonylureas
    • TZDs 
    • Oral Combination Therapy
  • Insulin
    • Insulin Glargine
    • Insulin Aspart
    • Human Insulin
    • Biosimilar Insulin
Breakup by Diabetes Type
  • Type 1
  • Type 2
Breakup by Distribution Channel
  • Online 
  • Hospital 
  • Retail Pharmacies
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Novo Nordisk A/S
  • Sanofi-aventis Groupe
  • Merck & Co., Inc.
  • Eli Lilly and Company.
  • AstraZeneca plc
  • Takeda Pharmaceutical Company Limited.
  • Novartis AG
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*We at Expert Market Research always strive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Diabetes Drugs Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Diabetes Drugs Historical Market (2017-2021) 
    8.3    Global Diabetes Drugs Market Forecast (2022-2027)
    8.4    Global Diabetes Drugs Market by Drugs 
        8.4.1    Oral Anti-diabetic Drugs
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2017-2021)
            8.4.1.3    Forecast Trend (2022-2027)
            8.4.1.4    Breakup by Type
                8.4.1.4.1    Alpha-glucosidase Inhibitors
                8.4.1.4.2    Biguanides
                8.4.1.4.3    Bile Acid Sequestrants
                8.4.1.4.4    Dopamine-2 Agonists
                8.4.1.4.5    DPP-4 inhibitors
                8.4.1.4.6    Meglitinides
                8.4.1.4.7    SGLT2 Inhibitors
                8.4.1.4.8    Sulfonylureas
                8.4.1.4.9    TZDs 
                8.4.1.4.10    Oral Combination Therapy
        8.4.2    Insulin
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2017-2021)
            8.4.2.3    Forecast Trend (2022-2027)
            8.4.2.4    Breakup by Type
                8.4.2.4.1    Insulin Glargine
                8.4.2.4.2    Insulin Aspart
                8.4.2.4.3    Human Insulin
                8.4.2.4.4    Biosimilar Insulin
    8.5    Global Diabetes Drugs Market by Diabetes Type
        8.5.1    Type 1
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2017-2021)
            8.5.1.3    Forecast Trend (2022-2027)
        8.5.2    Type 2
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2017-2021)
            8.5.2.3    Forecast Trend (2022-2027)
    8.6    Global Diabetes Drugs Market by Distribution Channel
        8.6.1    Online 
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2017-2021)
            8.6.1.3    Forecast Trend (2022-2027)
        8.6.2    Hospital 
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2017-2021)
            8.6.2.3    Forecast Trend (2022-2027)
        8.6.3    Retail Pharmacies
            8.6.3.1    Market Share
            8.6.3.2    Historical Trend (2017-2021)
            8.6.3.3    Forecast Trend (2022-2027)
    8.7    Global Diabetes Drugs Market by Region
        8.7.1    Market Share
            8.7.1.1    North America
            8.7.1.2    Europe
            8.7.1.3    Asia Pacific
            8.7.1.4    Latin America
            8.7.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2017-2021)
        9.1.2    Forecast Trend (2022-2027)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2017-2021)
        9.2.2    Forecast Trend (2022-2027)
        9.2.3    Breakup by Country 
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2017-2021)
        9.3.2    Forecast Trend (2022-2027)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2017-2021)
        9.4.2    Forecast Trend (2022-2027)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2017-2021)
        9.5.2    Forecast Trend (2022-2027)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    Key Indicators for Demand
    10.4    Key Indicators for Price
11    Value Chain Analysis
12    Competitive Landscape

    12.1    Market Structure
    12.2    Company Profiles
        12.2.1    Novo Nordisk A/S
            12.2.1.1    Company Overview
            12.2.1.2    Product Portfolio
            12.2.1.3    Demographic Reach and Achievements
            12.2.1.4    Certifications
        12.2.2    Sanofi-aventis Groupe
            12.2.2.1    Company Overview
            12.2.2.2    Product Portfolio
            12.2.2.3    Demographic Reach and Achievements
            12.2.2.4    Certifications
        12.2.3    Merck & Co., Inc.
            12.2.3.1    Company Overview
            12.2.3.2    Product Portfolio
            12.2.3.3    Demographic Reach and Achievements
            12.2.3.4    Certifications
        12.2.4    Eli Lilly and Company.
            12.2.4.1    Company Overview
            12.2.4.2    Product Portfolio
            12.2.4.3    Demographic Reach and Achievements
            12.2.4.4    Certifications
        12.2.5    AstraZeneca plc
            12.2.5.1    Company Overview
            12.2.5.2    Product Portfolio
            12.2.5.3    Demographic Reach and Achievements
            12.2.5.4    Certifications
        12.2.6    Takeda Pharmaceutical Company Limited.
            12.2.6.1    Company Overview
            12.2.6.2    Product Portfolio
            12.2.6.3    Demographic Reach and Achievements
            12.2.6.4    Certifications
        12.2.7    Novartis AG
            12.2.7.1    Company Overview
            12.2.7.2    Product Portfolio
            12.2.7.3    Demographic Reach and Achievements
            12.2.7.4    Certifications
        12.2.8    Others
13    Industry Events and Developments
 

List of Key Figures and Tables

1.    Global Diabetes Drugs Market: Key Industry Highlights, 2017 and 2027
2.    Global Diabetes Drugs Historical Market: Breakup by Drugs (USD Billion), 2017-2021
3.    Global Diabetes Drugs Market Forecast: Breakup by Drugs (USD Billion), 2022-2027
4.    Global Diabetes Drugs Historical Market: Breakup by Diabetes Type (USD Billion), 2017-2021
5.    Global Diabetes Drugs Market Forecast: Breakup by Diabetes Type (USD Billion), 2022-2027
6.    Global Diabetes Drugs Historical Market: Breakup by Distribution Channel (USD Billion), 2017-2021
7.    Global Diabetes Drugs Market Forecast: Breakup by Distribution Channel (USD Billion), 2022-2027
8.    Global Diabetes Drugs Historical Market: Breakup by Region (USD Billion), 2017-2021
9.    Global Diabetes Drugs Market Forecast: Breakup by Region (USD Billion), 2022-2027
10.    North America Diabetes Drugs Historical Market: Breakup by Country (USD Billion), 2017-2021
11.    North America Diabetes Drugs Market Forecast: Breakup by Country (USD Billion), 2022-2027
12.    Europe Diabetes Drugs Historical Market: Breakup by Country (USD Billion), 2017-2021
13.    Europe Diabetes Drugs Market Forecast: Breakup by Country (USD Billion), 2022-2027
14.    Asia Pacific Diabetes Drugs Historical Market: Breakup by Country (USD Billion), 2017-2021
15.    Asia Pacific Diabetes Drugs Market Forecast: Breakup by Country (USD Billion), 2022-2027
16.    Latin America Diabetes Drugs Historical Market: Breakup by Country (USD Billion), 2017-2021
17.    Latin America Diabetes Drugs Market Forecast: Breakup by Country (USD Billion), 2022-2027
18.    Middle East and Africa Diabetes Drugs Historical Market: Breakup by Country (USD Billion), 2017-2021
19.    Middle East and Africa Diabetes Drugs Market Forecast: Breakup by Country (USD Billion), 2022-2027
20.    Global Diabetes Drugs Market Structure

Key Questions Answered in the Report

In 2021, the global diabetic drug market attained a value of nearly USD 67.17 billion.

The market is projected to grow at a CAGR of 5.3% between 2022 and 2027.

The market is estimated to witness healthy growth in the forecast period of 2022-2027 to reach USD 91.57 billion by 2027.

The major drivers include the rapidly increasing diabetic population, rising investments in the R&D for better treatment, technological advancements, and the rising consumption of food with sugar, lack of exercise, and unhealthy diets.

The rising investment by the government in drug development is a key industry trend driving the market growth.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with Asia Pacific accounting for the largest share of the market.

The types of drugs can be divided into oral anti-diabetic drugs and insulin. Oral anti-diabetic drugs can be further divided into Alpha-glucosidase inhibitors, Biguanides, Bile Acid Sequestrants, Dopamine-2 Agonists, DPP-4 inhibitors, Meglitinides, SGLT2 Inhibitors, Sulfonylureas, TZDs, and oral combination therapy. Insulin can be further divided into Insulin Glargine, Insulin Aspart, Human Insulin, and Biosimilar Insulin.

The types of diabetes can be divided into Type 1 and Type 2.

The different distribution channels include online, hospital, and retail pharmacies.

The major players in the industry are Novo Nordisk A/S, Sanofi-aventis Groupe, Merck & Co. Inc., Eli Lilly and Company., AstraZeneca plc, Takeda Pharmaceutical Company Limited., and Novartis AG, among others.

Analyst Review

The global diabetes drugs market attained a value of USD 67.17 billion in 2021, driven by the rising prevalence of urinary incontinence among the growing geriatric population. Aided by the growing technological advancements, the market is expected to grow at the CAGR of 5.3% in the forecast period of 2022-2027. The market is projected to reach USD 91.57 billion by 2027.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its drugs, the market of diabetes drugs can be segmented into oral anti-diabetic drugs and insulin, whereas oral anti-diabetic drugs can be segmented into Alpha-glucosidase inhibitors, Biguanides, Bile Acid Sequestrants, Dopamine-2 Agonists, DPP-4 inhibitors, Meglitinides, SGLT2 Inhibitors, Sulfonylureas, TZDs, and oral combination therapy and the insulin can be segmented into insulin glargine, insulin aspart, human insulin, and biosimilar insulin, among others. On the basis of distribution channels, the market can be divided into online, hospital, and retail pharmacies. The types of diabetes can be divided into Type 1 and Type 2. The major regional markets for the global diabetes drug market are North America, Europe, Asia Pacific, Latin America, the Middle East and Africa, with Asia Pacific accounting for the largest share of the market. The key players in the above market include Novo Nordisk A/S, Sanofi-aventis Groupe, Merck & Co. Inc., Eli Lilly and Company., AstraZeneca plc, Takeda Pharmaceutical Company Limited., and Novartis AG, among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER